Equitable access in emerging markets: The next chapter of pharma growth in LMICs

Emerging markets are home to 85 percent of the global population but receive less than 10 percent of healthcare resources. The rising healthcare demands and unmet needs in low- and middle-income countries present an opportunity for pharma to align growth with impact. Discover strategies for equitable access and sustainable growth.

Over the past 20 years, emerging markets have been on the pharmaceutical industry’s radar, recognized for their growth potential and unmet medical needs. However, they were often not prioritized over established markets. With ongoing shifts in the global healthcare landscape, companies are now approaching these regions with a renewed focus on equitable access and long-term, sustainable growth.

85 percent of the world’s population resides in low- and middle-income countries (LMICs) accompanied by a substantial rise in non-communicable diseases (NCDs) and infectious disease burdens in these regions. However, despite contributing…